ERBB2 and female reproductive organ cancer: Although the HER2/neu status in female reproductive cancers has been investigated over the past two decades, determination of the HER2/neu status has not been well studied as a predictive biomarker for response to anti-HER2/neu treatment in the gynecologic cancers unlike in the breast and the digestive system.